Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Guttman

Showing results (301-310 of 387) with videos related to

Pageof 39
Sort By:
The Journal of Allergy and Clinical Immunology|July 30, 2019
Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitisAna B Pavel, Teresa Song, Hyun-Je Kim, et al.
The Journal of Investigative Dermatology|April 24, 2009
Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferationMark J Bluth, Lisa C Zaba, Dariush Moussai, et al.
Experimental Dermatology|October 28, 2020
The erythema Q-score, an imaging biomarker for redness in skin inflammationJohn Frew, Lauren Penzi, Mayte Suarez-Farinas, et al.
Journal of the American Academy of Dermatology|February 8, 2018
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose studyEmma Guttman-Yassky, Jonathan I Silverberg, Osamu Nemoto, et al.
Allergy|February 20, 2024
Transcriptomic evaluation of skin tape-strips in children with allergic asthma uncovers epidermal barrier dysfunction and asthma-associated biomarkers abnormalitiesEster Del Duca, Dante Dahabreh, Madeline Kim, et al.
Archives of Dermatological Research|March 1, 2022
A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areataDaniela Mikhaylov, Jacob W Glickman, Ester Del Duca, et al.
Allergy|October 22, 2022
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areataYael Renert-Yuval, Ana B Pavel, Ester Del Duca, et al.
Allergy|November 29, 2022
IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseasesCarlos J Aranda, Edgar Gonzalez-Kozlova, Sean P Saunders, et al.
American Journal of Clinical Dermatology|May 14, 2022
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)Andrew Blauvelt, Emma Guttman-Yassky, Amy S Paller, et al.
Journal of the American Academy of Dermatology|December 4, 2023
Tape strips detect molecular alterations and cutaneous biomarkers in skin of patients with hidradenitis suppurativaKristina Navrazhina, Yael Renert-Yuval, Saakshi Khattri, et al.
Pageof 39

Showing results (301-310 of 387) with videos related to

Sort By:
Pageof 39
The Journal of Allergy and Clinical Immunology|July 30, 2019
Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitisAna B Pavel, Teresa Song, Hyun-Je Kim, et al.
The Journal of Investigative Dermatology|April 24, 2009
Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferationMark J Bluth, Lisa C Zaba, Dariush Moussai, et al.
Experimental Dermatology|October 28, 2020
The erythema Q-score, an imaging biomarker for redness in skin inflammationJohn Frew, Lauren Penzi, Mayte Suarez-Farinas, et al.
Journal of the American Academy of Dermatology|February 8, 2018
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose studyEmma Guttman-Yassky, Jonathan I Silverberg, Osamu Nemoto, et al.
Allergy|February 20, 2024
Transcriptomic evaluation of skin tape-strips in children with allergic asthma uncovers epidermal barrier dysfunction and asthma-associated biomarkers abnormalitiesEster Del Duca, Dante Dahabreh, Madeline Kim, et al.
Archives of Dermatological Research|March 1, 2022
A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areataDaniela Mikhaylov, Jacob W Glickman, Ester Del Duca, et al.
Allergy|October 22, 2022
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areataYael Renert-Yuval, Ana B Pavel, Ester Del Duca, et al.
Allergy|November 29, 2022
IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseasesCarlos J Aranda, Edgar Gonzalez-Kozlova, Sean P Saunders, et al.
American Journal of Clinical Dermatology|May 14, 2022
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)Andrew Blauvelt, Emma Guttman-Yassky, Amy S Paller, et al.
Journal of the American Academy of Dermatology|December 4, 2023
Tape strips detect molecular alterations and cutaneous biomarkers in skin of patients with hidradenitis suppurativaKristina Navrazhina, Yael Renert-Yuval, Saakshi Khattri, et al.
Pageof 39